Iovance Biotherapeutics Inc. has entered into an amended and restated open market sale agreement with Jefferies LLC, allowing for an at-the-market offering program. Under this arrangement, Iovance can issue and sell up to $350 million of its common stock, with each share valued at $0.000041666. The sales, conducted through Jefferies as the sales agent, will be carried out in compliance with Rule 415 of the Securities Act of 1933. Jefferies will earn a commission of up to 3% of the gross sales proceeds. The agreement includes customary representations, warranties, and covenants, and Iovance has agreed to indemnify Jefferies against certain liabilities. The offering will terminate upon the agreement's termination.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-081953), on August 22, 2025, and is solely responsible for the information contained therein.